These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date 2009-014409-15 Prospective, randomized, multicenter, open label phase II study to access efficacy and safety of Lucentis monotherapy (ranibizumab 0.5 mg intravitreal injections) compared with Lucentis plus panretina... bad-data
Ongoing 2009-014612-34 Prospective, multicenter, open-label study to evaluate the safety and efficacy of intravitreal ranibizumab in patients with subfoveal or juxtafoveal choroidal neovascularization (CNV) secondary to oth... not-yet-due
Reported results 2009-016760-36 Prospective, randomized, open label phase II study to assess efficacy and safety of Macugen® (pegaptanib 0.3 mg intravitreal injections) plus panretinal photocoagulation (PRP) and PRP (monotherapy) in... 2012-10-31 due-trials
Not reported 2013-001215-73 Open, randomized and crossed-over study on the bioequivalence between tablets of 40 mg of furosemide from Ratiopharm - Comércio e Indústria de Produtos Farmacêuticos, Lda. (Furosemida Ratiopharm 40 mg... 2013-10-11 due-trials
Not reported 2013-001542-34 Open, randomized and crossed-over study on the bioequivalence between soft capsules of 100 mg of ciclosporine from Novartis Farma – Produtos Farmacêuticos, S.A. (Sandimmun Neoral®) and from Generis Fa... 2014-03-28 due-trials
Not reported 2013-003490-10 Intraocular Pressure And Tolerability Study of Preservative Free Bimatoprost 0.03% Unit Dose (BUDPF) or preservative free Latanoprost 0.005% Unit Dose (LUDPF) (Monopost)in patients with Ocular hyperte... 2015-02-17 due-trials
Reported results 2013-003640-23 Prospective, randomized, multicentre, open label, phase II / III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP in ... 2016-05-27 due-trials
Not reported 2014-003491-23 A non-randomised, open-label, multicenter phase 4 pilot study on the effect and safety of Iluvien® in chronic diabetic macular edema patients considered insufficiently responsive to available therapie... 2016-03-09 due-trials
Not reported 2015-001368-20 A Randomized, Double-masked, Sham-controlled Phase 4 Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therap... 2018-09-05 due-trials